Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

The Commercial Sickness Fund - KKH (hereinafter KKH) aims to conclude discount contracts pursuant to Section 130a, paragraph 8, SGB V with all suitable pharmaceutical companies for the active substance(s) in question within the framework of a so-called "Open-House" procedure. By specifying uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the opportunity to conclude or join a discount contract pursuant to Section 130a, paragraph 8, SGB V for the active substance specified in the invitation to tender. Interested pharmaceutical companies can request the participation documents and the contract from the contact address given ([email protected]).